Microcephaly-cardiomyopathy syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2515OMIM:251220Q87.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Microcephaly-cardiomyopathy syndrome is an extremely rare genetic condition in which a baby is born with an abnormally small head (microcephaly) along with a weakened or enlarged heart muscle (cardiomyopathy). The small head size reflects reduced brain growth, which typically leads to intellectual disability and developmental delays. The heart problems can range from a thickened heart muscle (hypertrophic cardiomyopathy) to a dilated, weakened heart (dilated cardiomyopathy), both of which can impair the heart's ability to pump blood effectively. Additional features that have been reported in some affected individuals include short stature, seizures, and distinctive facial features. Because so few cases have been described in the medical literature, the full range of symptoms and their severity is not completely understood. There is currently no cure for this condition. Treatment focuses on managing symptoms, particularly supporting heart function with medications and addressing developmental delays through early intervention therapies such as physical therapy, occupational therapy, and speech therapy. Regular monitoring by a team of specialists is essential to manage the complex needs of affected individuals. The condition is also sometimes referred to as microcephaly with cardiomyopathy.

Also known as:

Key symptoms:

Abnormally small head at birthWeakened or enlarged heart muscleIntellectual disabilityDelayed development of motor skillsDelayed speech and languageShort statureSeizuresPoor weight gain and failure to thriveDistinctive facial featuresLow muscle toneBreathing difficulties related to heart problemsFatigue and poor feeding in infancy

Clinical phenotype terms (15)— hover any for plain English
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Microcephaly-cardiomyopathy syndrome.

View clinical trials →

No actively recruiting trials found for Microcephaly-cardiomyopathy syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Microcephaly-cardiomyopathy syndrome community →

No specialists are currently listed for Microcephaly-cardiomyopathy syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Microcephaly-cardiomyopathy syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Microcephaly-cardiomyopathy syndromeForum →

No community posts yet. Be the first to share your experience with Microcephaly-cardiomyopathy syndrome.

Start the conversation →

Latest news about Microcephaly-cardiomyopathy syndrome

No recent news articles for Microcephaly-cardiomyopathy syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe is my child's cardiomyopathy, and what type is it?,What signs of heart failure should I watch for at home?,Are there genetic tests that can identify the exact cause in our family?,What developmental therapies should we start, and how often?,Is my child at risk for seizures, and how would we manage them?,What is the long-term outlook for my child's heart and brain development?,If we plan to have more children, what is the chance they could be affected?

Common questions about Microcephaly-cardiomyopathy syndrome

What is Microcephaly-cardiomyopathy syndrome?

Microcephaly-cardiomyopathy syndrome is an extremely rare genetic condition in which a baby is born with an abnormally small head (microcephaly) along with a weakened or enlarged heart muscle (cardiomyopathy). The small head size reflects reduced brain growth, which typically leads to intellectual disability and developmental delays. The heart problems can range from a thickened heart muscle (hypertrophic cardiomyopathy) to a dilated, weakened heart (dilated cardiomyopathy), both of which can impair the heart's ability to pump blood effectively. Additional features that have been reported in s

How is Microcephaly-cardiomyopathy syndrome inherited?

Microcephaly-cardiomyopathy syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Microcephaly-cardiomyopathy syndrome typically begin?

Typical onset of Microcephaly-cardiomyopathy syndrome is neonatal. Age of onset can vary across affected individuals.